No Data
The New York Stock Exchange Leads Industry in Global IPO Proceeds for the First Half of 2024
NYSE issuers raise $12 billion as IPO activity builds momentum Welcomes 7 of the 10 largest U.S. transactions The Big Board continues to drive exchange transfers The New York Stock Exchange, part of
Investors in 3M (NYSE:MMM) Have Unfortunately Lost 30% Over the Last Three Years
3M Company (NYSE:MMM) shareholders should be happy to see the share price up 10% in the last quarter. But that cannot eclipse the less-than-impressive returns over the last three years. Truth be t
3M Company (NYSE:MMM) Is a Favorite Amongst Institutional Investors Who Own 66%
To get a sense of who is truly in control of 3M Company (NYSE:MMM), it is important to understand the ownership structure of the business.
GTJA: Innovent Bio's Marziditide is expected to be approved by 25H1, maintaining a "shareholding" rating.
GTJA released a research report stating that Innovent Bio (01801) had intensive clinical data readings on its integrated pipeline and tumor pipeline. PD-1/IL2, CLND18.2ADC, and CLDN18.2/CD3 clinical data were excellent, and Marizomib is expected to be approved soon with enormous market potential. GTJA maintains a 'shareholding' rating, stating that it is optimistic about the company's integrated pipeline and Marizomib's layout in the IO+ADC tumor field, and its increase in domestic sales. GTJA's main viewpoints are as follows: Marizomib effectively reduces weight and decreases liver fat by more than 80%, indicating its potential entry into the MASH treatment market. According to GLOR.
XLI: 3M, GE Aerospace Among Industrial Gainers During the Second Quarter; American Airlines Among Laggards
3M Young Scientist Challenge Announces 2024 National Finalists